Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lorlatinib in Patients With Advanced Non-Small Cell Lung Cancer Who Progress on First- and Second- Generation Tyrosine Kinase Inhibitor: A Real-world Evidence Among Taiwanese Population, Non-Interventional Study

NCT06282991 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06282991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06282991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lorlatinib in Patients With Advanced Non-Small Cell Lung Cancer Who Progress on First- and Second- Generation Tyrosine Kinase Inhibitor: A Real-world Evidence Among Taiwanese Population, Non-Interventional Study
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
July 22, 2020
Completion date
January 18, 2021
Enrollment
73 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung carcinoma